DK1692105T3 - Fremgangsmåde til fremstilling af (3-oxo-2,3-dihydro-1H-isoindol-1-yl)-acetylguanidin-derivater - Google Patents

Fremgangsmåde til fremstilling af (3-oxo-2,3-dihydro-1H-isoindol-1-yl)-acetylguanidin-derivater

Info

Publication number
DK1692105T3
DK1692105T3 DK04803188T DK04803188T DK1692105T3 DK 1692105 T3 DK1692105 T3 DK 1692105T3 DK 04803188 T DK04803188 T DK 04803188T DK 04803188 T DK04803188 T DK 04803188T DK 1692105 T3 DK1692105 T3 DK 1692105T3
Authority
DK
Denmark
Prior art keywords
isoindol
dihydro
oxo
preparation
acetylguanidine
Prior art date
Application number
DK04803188T
Other languages
English (en)
Inventor
Gerrit Schubert
Joerg Rieke-Zapp
Johannes Keil
Heinz-Werner Kleemann
Reda Hanna
Bao-Guo Huang
Xiao-Dong Wu
Yves Gouraud
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1692105T3 publication Critical patent/DK1692105T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DK04803188T 2003-12-02 2004-11-19 Fremgangsmåde til fremstilling af (3-oxo-2,3-dihydro-1H-isoindol-1-yl)-acetylguanidin-derivater DK1692105T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10356717A DE10356717A1 (de) 2003-12-02 2003-12-02 Verfahren zur Herstellung von (3-Oxo-2,3-dihydro-1H-isoindol-1-yl)-acetylguanidin-Derivaten
PCT/EP2004/013153 WO2005054195A1 (de) 2003-12-02 2004-11-19 VERFAHREN ZUR HERSTELLUNG VON (3-OXO-2,3-DIHYDRO-1H-ISOINDOL-1-Yl)-ACETYLGUANIDIN-DERIVATEN

Publications (1)

Publication Number Publication Date
DK1692105T3 true DK1692105T3 (da) 2008-08-25

Family

ID=34638338

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04803188T DK1692105T3 (da) 2003-12-02 2004-11-19 Fremgangsmåde til fremstilling af (3-oxo-2,3-dihydro-1H-isoindol-1-yl)-acetylguanidin-derivater

Country Status (38)

Country Link
EP (1) EP1692105B1 (da)
JP (1) JP4809774B2 (da)
KR (1) KR101202604B1 (da)
CN (1) CN100526297C (da)
AR (1) AR046733A1 (da)
AT (1) ATE395334T1 (da)
AU (1) AU2004295056B2 (da)
BR (1) BRPI0417147A (da)
CA (1) CA2548020C (da)
CR (1) CR8376A (da)
CY (1) CY1108187T1 (da)
DE (2) DE10356717A1 (da)
DK (1) DK1692105T3 (da)
EC (1) ECSP066597A (da)
EG (1) EG25498A (da)
ES (1) ES2304634T3 (da)
HK (1) HK1097525A1 (da)
HR (1) HRP20080253T3 (da)
IL (1) IL175834A (da)
JO (1) JO2498B1 (da)
MA (1) MA28220A1 (da)
MY (1) MY136467A (da)
NO (1) NO20063058L (da)
NZ (1) NZ547625A (da)
OA (1) OA13293A (da)
PA (1) PA8618701A1 (da)
PE (1) PE20051037A1 (da)
PL (1) PL1692105T3 (da)
PT (1) PT1692105E (da)
RS (1) RS50571B (da)
RU (1) RU2397159C2 (da)
SI (1) SI1692105T1 (da)
TN (1) TNSN06167A1 (da)
TW (1) TWI334348B (da)
UA (1) UA83883C2 (da)
UY (1) UY28648A1 (da)
WO (1) WO2005054195A1 (da)
ZA (1) ZA200603338B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200812962A (en) * 2006-07-12 2008-03-16 Astrazeneca Ab New compounds I/418
WO2009128421A1 (ja) * 2008-04-16 2009-10-22 キッセイ薬品工業株式会社 ピラゾール誘導体の１／２フマル酸塩
RU2518740C1 (ru) * 2013-03-22 2014-06-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" СРЕДСТВО, ИНГИБИРУЮЩЕЕ Na+/H+-ОБМЕН, И ДИГИДРОХЛОРИД 2-(3,4-МЕТИЛЕНДИОКСИФЕНИЛ)-9-МОРФОЛИНОЭТИЛИМИДАЗО[1,2-a]БЕНЗИМИДАЗОЛА
CN107778238B (zh) * 2016-08-29 2022-07-22 中山大学 一种3，4-二氢异喹啉-1-酮的合成新方法
CN107286074B (zh) * 2017-08-16 2019-08-20 厦门华厦学院 3-羟基异吲哚-1-酮衍生物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946842A (en) * 1985-07-05 1990-08-07 Smith Kline & French Laboratories Limited Novel guanidino pyridazinones as cardiac stimulants
DE19737224A1 (de) * 1997-08-27 1999-03-18 Hoechst Marion Roussel De Gmbh Pharmazeutisches Kombinationspräparat aus einem Inhibitor des Natrium-Wasserstoff-Austauschers und einem Arzneimittel zur Behandlung von Herz-Kreislauferkrankungen
DE19832429A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE60216747T2 (de) * 2001-04-09 2007-10-04 Novartis Vaccines and Diagnostics, Inc., Emeryville Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten
FR2840302B1 (fr) * 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant

Also Published As

Publication number Publication date
RS50571B (sr) 2010-05-07
AR046733A1 (es) 2005-12-21
HK1097525A1 (en) 2007-06-29
CA2548020C (en) 2013-01-08
CA2548020A1 (en) 2005-06-16
TW200526207A (en) 2005-08-16
CN100526297C (zh) 2009-08-12
NO20063058L (no) 2006-06-30
MY136467A (en) 2008-10-31
OA13293A (en) 2007-01-31
WO2005054195A1 (de) 2005-06-16
PE20051037A1 (es) 2005-12-29
EG25498A (en) 2012-01-22
JO2498B1 (en) 2009-10-05
UA83883C2 (en) 2008-08-26
EP1692105B1 (de) 2008-05-14
ZA200603338B (en) 2007-06-27
PT1692105E (pt) 2008-07-04
TWI334348B (en) 2010-12-11
DE502004007177D1 (de) 2008-06-26
PL1692105T3 (pl) 2008-09-30
AU2004295056B2 (en) 2011-04-14
JP2007516243A (ja) 2007-06-21
ES2304634T3 (es) 2008-10-16
KR20060111558A (ko) 2006-10-27
RU2397159C2 (ru) 2010-08-20
SI1692105T1 (sl) 2008-08-31
TNSN06167A1 (en) 2007-11-15
MA28220A1 (fr) 2006-10-02
CY1108187T1 (el) 2014-02-12
HRP20080253T3 (en) 2008-09-30
ATE395334T1 (de) 2008-05-15
IL175834A (en) 2010-12-30
CR8376A (es) 2007-12-04
CN1886374A (zh) 2006-12-27
ECSP066597A (es) 2006-10-25
PA8618701A1 (es) 2006-07-03
BRPI0417147A (pt) 2007-03-06
JP4809774B2 (ja) 2011-11-09
EP1692105A1 (de) 2006-08-23
UY28648A1 (es) 2005-06-30
IL175834A0 (en) 2006-10-05
DE10356717A1 (de) 2005-07-07
KR101202604B1 (ko) 2012-11-19
RU2006123410A (ru) 2008-01-10
AU2004295056A1 (en) 2005-06-16
NZ547625A (en) 2010-01-29

Similar Documents

Publication Publication Date Title
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK2058243T4 (da) Fremgangsmåde til fremstilling af drikke
DK1611108T3 (da) Fremgangsmåde til fremstilling af telmisartan
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
IS7755A (is) Aðferð við framleiðslu á (S,S)-cis-2-benshýdríl-3-bensýlamínókínuklídín
DK1667967T3 (da) Fremgangsmåde til fremstilling af 2-oxo-1-pyrrolidin-derivater
DK1546122T3 (da) Fremgangsmåde til fremstilling af valsartan
NO20052262D0 (no) Fremgangsmate til fremstilling av 4-substituerte 2,2,6,6-tetrametyl-piperidin-N-oksy- og 2,2,6,6-tetrametyl-piperidin-N-hydroksy-forbindelser
DK1831223T3 (da) Fremgangsmåde til fremstilling af L-biopterin
DK1838683T3 (da) Fremgangsmåde til fremstilling af [1,4,5]-oxadiazepinderivater
DK1881830T3 (da) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-derivater til behandling af infertilitet
NO20041415L (no) Fremgangsmate for fremstilling av metanol
NO20044814L (no) Fremgangsmate for fremstilling av combretastaniner
IS7958A (is) Aðferð til að framleiða metýl 2-dífenýlmetýlsúlfínýlasetat
DK1678135T3 (da) Fremgangsm de til fremstilling af n-amino-substituerede hetorocykliske forbindelser
DK1575941T3 (da) Fremgangsmåde til fremstilling af (S)-pantoprazol
DK1682541T3 (da) Fremgangsmåde til fremstilling af tiotropiumsalte
DK1912961T3 (da) Fremgangsmåde til fremstilling af bepromolin
DK1656365T3 (da) Fremgangsmåde til fremstilling af enantiomerisk rent mirtazapin
DK1511724T3 (da) Fremgangsmåde til fremstilling af thioalkylaminderivater
DK1692105T3 (da) Fremgangsmåde til fremstilling af (3-oxo-2,3-dihydro-1H-isoindol-1-yl)-acetylguanidin-derivater
DK1888613T3 (da) Fremgangsmåde til fremstilling af thiophenglycosidderivater
DK1692137T3 (da) Fremgangsmåde til fremstilling af tubulinininhibitorer